Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi To Advance Kymera’s IRAK4 Protein Degrader After Phase I Success

But Some Analysts Advise Caution

Executive Summary

The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.

You may also be interested in...



Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset

The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.

Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel